课题基金 / 基金详情

项目摘要

项目成果

Nicholas F. LaRusso的其他基金

相似基金

相关文献

中文摘要
翻译
项目概要:行政核心 C-SiG行政核心的目标是为中心的总体方向提供领导 并优化中心计划和核心的会员权益。C-SiG行政核心领导是 由N.F.博士提供。LaRusso主任、G. J. Gores博士联合主任和V.H.博士Shah,副主任, 与执行委员会、内部咨询委员会和外部咨询委员会一起 以马克思执行委员会由董事、联席董事、副董事、核心 董事,机制研究主题组(细胞内信号,细胞到细胞)的领导者 传播和遗传学/表观遗传学),以及胃肠病学和 肝病学,每月一次。内部咨询委员会每季度举行一次会议, 就中心的战略方向向执行委员会提供意见,并促进沟通 外部咨询委员会由五位国际知名人士组成, 研究人员是消化系统疾病研究的领导者,每年亲自或通过会议会面 根据需要定期向执行委员会提供反馈。管理员提供 为中心的实时财务管理和运作提供必要的支持。新招募的核心 项目经理执行日常核心项目管理,以提高核心流程的标准化, 简化工作流程的效率,并提高交付的质量。行动委员会的成员包括 主任、联合主任、管理员和核心项目经理,每周开会计划和管理C- SiG操作。行政领导层确保C-SiG核心能够响应 成员,并对核心职能进行监督。C-SiG的目标是通过以下方式促进细胞信号科学: i)通过扩大现有地理标志的技术和合作能力,促进多学科研究 科学家和吸引其他学科的研究人员; ii)识别和培养新的GI研究人员 通过同行评审的试点和可行性(P/F)计划,包括职业发展研讨会,课程, 和结构化的指导(19/26,73%的P/F接受者获得联邦资助); 专门的设备、技术、方法、试剂和专业知识(光学显微镜,临床, 以及基因编辑和表观基因组学核心),核心菜单持续更新、质量保证和 (四)支持健全的项目管理体系, 富集计划;以及v)促进C-SiG与马约的其他NIDDK中心之间的互动 (e.g., PKD中心)和现有的DDRCC,特别是在中西部(即,中西部DDRCC联盟)。
英文摘要
PROJECT SUMMARY: ADMINISTRATIVE CORE The objective of the C-SiG Administrative Core is to provide leadership for the overall direction of the Center and to optimize member benefits from Center Programs and Cores. C-SiG Administrative Core leadership is provided by Dr. N.F. LaRusso, Director, Dr. G.J. Gores, Co-Director, and Dr. V.H. Shah, Associate Director, in conjunction with an Executive Committee, an Internal Advisory Committee, and an External Advisory Committee. The Executive Committee is comprised of the Director, Co-Director, Associate Directors, Core Directors, the Leaders of the Mechanistic Research Theme groups (Intracellular Signaling, Cell-to-Cell Communication, and Genetics/Epigenetics), and key leaders within the Division of Gastroenterology and Hepatology, and meets monthly. The Internal Advisory Committee meets quarterly and provides regular input to the Executive Committee regarding the strategic direction of the Center and facilitates communication with institutional leaders The External Advisory Committee consists of five internationally prominent investigators who are leaders in digestive disease research and meets annually in person and by conference call as needed to provide regular feedback to the Executive Committee. An Administrator provides the necessary support for real-time financial management and operations of the Center. A newly recruited Core Project Manager performs day-to-day Core project management to improve standardization of core processes, streamline efficiency of workflows, and enhance deliverable quality. The Operations Committee consists of the Director, Co-director, Administrator and Core Project Manager and meets weekly to plan and manage C- SiG operations. The administrative leadership assures responsiveness of the C-SiG Cores to the needs of the members and provides oversight for Core functions. C-SiG's goals are to promote cell signaling science by: i) Fostering multidisciplinary research by expanding technical and collaborative capabilities of established GI scientists and attracting investigators from other disciplines; ii) Identifying and nurturing new GI investigators via a peer-reviewed Pilot and Feasibility (P/F) Program including career development workshops, curricula, and structured mentorship (19/26, 73% of P/F recipients achieving federal funding); iii) Offering core-based specialized equipment, technologies, methodologies, reagents, and expertise (Optical Microscopy, Clinical, and Gene Editing and Epigenomics Cores), with continuous core menu updates, quality assurance and assessments, and project management oversight in response to member feedback; iv) Supporting a robust Enrichment Program; and v) Promoting interactions between C-SiG with other NIDDK centers at Mayo (e.g., PKD Center) and existing DDRCCs, especially in the Midwest (i.e., Midwest DDRCC Alliance).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Midwest DDRCC Alliance Conference (Hosted by the Mayo Clinic DDRCC)
  • 批准号:
    10675868
  • 项目类别:
  • 资助金额:
    $2.2万
  • 财政年份:
    2023
  • 负责人:
    Nicholas F. LaRusso
  • 依托单位:
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies
海外基金